2022
Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization
Adam LC, Savic LJ, Chapiro J, Letzen B, Lin M, Georgiades C, Hong KK, Nezami N. Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization. Clinical Imaging 2022, 89: 112-119. PMID: 35777239, PMCID: PMC9470015, DOI: 10.1016/j.clinimag.2022.06.013.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionHepatic metastasesResponse assessment methodsPartial responseTransarterial chemoembolizationResponse assessmentTumor primaryStratification of responseRare primary tumorResponse Evaluation CriteriaRetrospective bicentric studyAssessment of responseQuantitative European AssociationLiver metastasesMajor complicationsBicentric studyPrimary tumorRare tumorEarly surrogateTreatment responseCT scanPatientsRECISTSolid tumors
2016
3:36 PMAbstract No. 53 Which response criteria can predict early tumor response in CT image in hepatocellular carcinoma patients treated with TACE: RECIST, mRECIST, EASL or qEASL?
Zhao Y, Sahu S, Bai W, Schernthaner R, Duran R, Chapiro J, Yin Z, Lin M, Han G, Geschwind J. 3:36 PMAbstract No. 53 Which response criteria can predict early tumor response in CT image in hepatocellular carcinoma patients treated with TACE: RECIST, mRECIST, EASL or qEASL? Journal Of Vascular And Interventional Radiology 2016, 27: s28. DOI: 10.1016/j.jvir.2015.12.084.Peer-Reviewed Original Research